Pagaya Q1 Beats on Revenue, Costs; Guidance Raised, but Execution-Fee Trend Unchanged

What happened

Pagaya reported Q1 earnings that beat estimates on higher revenues and lower expenses, leading to a 4.5% stock gain and raised 2026 net income guidance. Despite the positive headline, the stock remains well below its 52-week high, reflecting persistent market skepticism. The beat does not address the core thesis risk: negative capital markets execution fees and credit reserve builds that plagued prior quarters. Until the next filing confirms those metrics have improved, the underlying funding-cost pressure remains unresolved. The raised guidance is encouraging but insufficient to shift the wait-and-see posture.

Implication

The Q1 results show operational momentum, but the market still lacks proof that spread compression is easing. Without evidence that execution fees are no longer negative and allowance for credit losses is steady, the stock remains vulnerable to funding-cost shocks. Investors should wait for at least one more quarter of observable improvement before considering a position. The raised guidance provides a ceiling, but the downside from spread widening remains asymmetric. A confirmed positive turn in execution fees and stable credit would justify re-evaluating at the $10 entry level.

Thesis delta

No change. The master report already accounted for a wide range of outcomes and conditioned re-entry on positive execution fees and stable reserves. Q1 beat does not provide that evidence. The net income guidance raise is positive but does not alter the fundamental uncertainty around funding economics. Therefore, the thesis remains WAIT with same conviction and thresholds.